Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference

Monopar Therapeutics Inc., a leading clinical-stage biopharmaceutical company dedicated to revolutionizing cancer treatment, is set to make a significant impact at the upcoming Roth MKM 2023 Healthcare Opportunities Conference. The event, scheduled for October 12, 2023, at The Yale Club in New York City, will provide an ideal platform for Monopar’s Chief Operating Officer, Andrew J. Cittadine, to present the company’s groundbreaking advancements in cancer therapeutics.

Monopar Therapeutics is at the forefront of developing innovative treatments that hold immense promise for cancer patients. With a robust pipeline consisting of cutting-edge therapies, the company is poised to make a remarkable difference in the lives of those battling this devastating disease.

One of the key highlights of Monopar’s pipeline is camsirubicin, currently in Phase 1b clinical trials for the treatment of advanced soft tissue sarcoma. This groundbreaking therapy has the potential to transform the treatment landscape for patients suffering from this challenging form of cancer. By targeting the underlying mechanisms of the disease, camsirubicin offers hope for improved outcomes and a better quality of life.

In addition to camsirubicin, Monopar is also developing MNPR-101, a late-stage preclinical antibody designed for radiopharmaceutical use in advanced cancers. This promising therapy has shown great potential in targeting and eradicating cancer cells, offering a beacon of hope for patients with advanced-stage cancers. With its advanced stage of development, MNPR-101 is on the cusp of making a significant impact in the field of radiopharmaceuticals.

Furthermore, Monopar is exploring the potential of MNPR-202, an early-stage camsirubicin analog that holds promise for various cancers. This exciting development showcases the company’s commitment to pushing the boundaries of cancer treatment and finding novel solutions to combat this complex disease.

Monopar’s participation in the Roth MKM 2023 Healthcare Opportunities Conference underscores the company’s dedication to sharing its groundbreaking research and advancements with the broader healthcare community. By presenting at this prestigious event, Monopar aims to foster collaboration, attract potential partners, and garner support for its mission to transform cancer treatment.

Investors and industry professionals attending the conference will have the opportunity to gain valuable insights into Monopar’s innovative therapies and the potential they hold for cancer patients. Andrew J. Cittadine, Monopar’s Chief Operating Officer, will provide a comprehensive overview of the company’s progress, highlighting the significant strides made in developing effective treatments that address the unmet needs of cancer patients.

As Monopar continues to make remarkable progress in the field of cancer therapeutics, the company remains committed to its mission of improving patient outcomes and enhancing the quality of life for those affected by cancer. With a strong focus on innovation and a robust pipeline of groundbreaking therapies, Monopar is poised to revolutionize cancer treatment and bring hope to countless individuals and their families.

For more information about Monopar Therapeutics Inc. and its groundbreaking research, please visit their website at Stay updated on the latest developments by following Monopar on social media platforms such as Twitter (@MonoparTx) and LinkedIn (Monopar Therapeutics).

Leave a comment